Researchers at the Mayo Clinic in Florida may have discovered a new treatment option for women with advanced ovarian cancer. Their discovery involves combining two well-known cancer drugs (ixabepilone and sunitinub) that had never been used in combination before nor had they ever been used in treating ovarian cancer. The result: 70% destruction of cancer cells already resistant to commonly used chemotherapy agents.
Potential NEW Treatment Option for Ovarian Cancer
It is estimated that over 21,000 women a year are diagnosed with ovarian cancer. When ovarian cancer is caught in it’s early stages (Stage 1 and still confined to the ovary), a woman has up to a 94% chance of long term survival. However, more than 70% of women with ovarian cancer aren’t diagnosed until the disease has advanced to Stage III or Stage IV. When caught at these late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it.
Initial research has shown that combining ixabepilone and sunitinub reduces the chemo-resistance in women with advanced ovarian cancer. The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by this drug combination. In a nutshell, when RhoB increases, cancer cells die.
Currently, neither ixabepilone nor sunitinub is approved for the treatment of ovarian cancer. “Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.”
If you know anyone diagnosed with advanced ovarian cancer, pass this information on to them so they can check it out with their doctors. Knowledge is power… share the power!